Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors

OBJECTIVE: To review literature on the impact of The Food and Drug Administration (FDA) drug risk communications on medication utilization, health care services use, and health outcomes. DATA SOURCES: The authors searched MEDLINE and the Web of Science for manuscripts published between January 1990 and November 2010 that included terms related to drug utilization, the FDA, and advisories or warnings. We manually searched bibliographies and works citing selected articles and consulted with experts to guide study selection. STUDY SELECTION: Studies were included if they involved an empirical analysis evaluating the impact of an FDA risk communication. DATA EXTRACTION: We extracted the drug(s) analyzed, relevant FDA communication(s), data source, analytical method, and main outcome(s) assessed. RESULTS: Of the 1432 records screened, 49 studies were included. These studies covered 16 medicines or therapeutic classes; one third examined communications regarding antidepressants. Most used medical or pharmacy claims and a few rigorously examined patient-provider communication, decision making, or risk perceptions. Advisories recommending increased clinical or laboratory monitoring generally led to decreased drug use, but only modest, short-term increases in monitoring. Communications targeting specific subpopulations often spilled over to other groups. Repeated or sequential advisories tended to have larger but delayed effects and decreased incident more than prevalent use. Drug-specific warnings were associated with particularly large decreases in utilization, although the magnitude of substitution within therapeutic classes varied across clinical contexts. CONCLUSIONS: Although some FDA drug risk communications had immediate and strong impacts, many had either delayed or had no impact on health care utilization or health behaviors. These data demonstrate the complexity of using risk communication to improve the quality and safety of prescription drug use, and suggest the importance of continued assessments of the effect of future advisories and label changes. Identifying factors that are associated with rapid and sustained responses to risk communications will be important for informing future risk communication efforts

Drug · Environmental health · Family medicine · Food and drug administration · Health care · Medical emergency · Medical record · MEDLINE · Medication Adherence and Compliance · Medicine · Pharmaceutical industry and healthcare · Pharmacology · Pharmacovigilance and Adverse Drug Reactions · Pharmacy

• The Impact of Emerging Safety and Effectiveness Evidence on the Use of Physician-administered Drugs

  Rena M Conti, Stacie B Dusetzina et al.•Medical Care•2013

  Añadir item

• Interrupted Time Series Analysis of Changes in Zolpidem Use Due to Media Broadcasts

  Open Access•Bo Ram Yang, Bo-Ram Yang et al.•International Journal of…•2021

  Añadir item

• Can public education campaigns equitably counter the use of substandard and falsified medical products in African countries

  Open Access•Janelle Wagnild, Samuel Asiedu Owusu et al.•Health Policy and Planning•2025

  Añadir item

• Framing of risk and preferences for annual and multi-year flood insurance

  Open Access•W J Wouter Botzen, John De Boer et al.•Journal of Economic Psychology•2013

  Añadir item

• Prescriber-Level Responses to the 2018–2019 Valsartan, Irbesartan, and Losartan Recalls and Drug Shortages

  Katherine Callaway Kim, Julie M Donohue et al.•Medical Care•2025

  Añadir item

• Disparities in Discontinuing Rosiglitazone Following the 2007 FDA Safety Alert

  Danya M Qato, Amal N Trivedi et al.•Medical Care•2016

  Añadir item

• Communicating the Risks of Medicines

  Gerald J Dal Pan•Medical Care•2012

  Añadir item

• Near Real-time Surveillance for Consequences of Health Policies Using Sequential Analysis

  Christine Y Lu, Robert B Penfold et al.•Medical Care•2018

  Añadir item

• Risk Perception and Communication Unplugged

  Open Access•Baruch Fischhoff•Risk Analysis•1995

  Añadir item

• Clinical Prescribing (and Off-Label Use) in a Second-Best World

  G Caleb Alexander•Medical Care•2010

  Añadir item

• Impact of the 2004 Food and Drug Administration Pediatric Suicidality Warning on Antidepressant and Psychotherapy Treatment for New-Onset Depression

  Satish Valluri, Julie M Zito et al.•Medical Care•2010

  Añadir item